Zhou X D, Tang Z Y, Yu Y Q, Ma Z C, Xu D B, Bao Y M, Yang R, Zhang M, Zhou M
Liver Cancer Institute, Shanghai Medical University.
Chin Med J (Engl). 1991 Oct;104(10):846-50.
During the period of 1958-1989, 356 patients with pathologically proven primary liver cancer (PLC) were determined by laparotomy to be unresectable. Of the 356 patients, 51 (14.3%) were of subclinical stage, 287 (80.6%) of moderate stage and 18 (5.1%) of late stage. The association of liver cirrhosis was present in 310 patients (87.1%). Treatment modalities in 356 patients were divided into 4 groups: hepatic artery ligation (HAL) (51), hepatic artery infusion (HAI) of chemotherapeutic agents (114), HAL + HAI (117), and HAL + HAI + radiotherapy (74). The 5-year survival rate was zero in the 4 groups in the period of 1958-1977. During 1978-1989, however, the 5-year survival rate was zero in HAL, 7.9% in HAI, 24.4% in HAL + HAI (with second look resection in 10 patients), and 36.5% in HAL + HAI + radiotherapy (with second look resection in 19). The marked improvement in survival in later period was attributable to the accurate site of hepatic artery catheter, longer infusion chemotherapy, and combination treatment, particularly second look resection in some of the patients. These results indicate that HAL + HAI + combination treatment might provide a possible prolongation of survival or even resection in some patients with original unresectable PLC.
在1958年至1989年期间,356例经病理证实的原发性肝癌(PLC)患者经剖腹探查确定为无法切除。在这356例患者中,51例(14.3%)处于亚临床期,287例(80.6%)处于中期,18例(5.1%)处于晚期。310例患者(87.1%)伴有肝硬化。356例患者的治疗方式分为4组:肝动脉结扎术(HAL)(51例)、肝动脉化疗药物灌注(HAI)(114例)、HAL+HAI(117例)以及HAL+HAI+放疗(74例)。在1958年至1977年期间,这4组的5年生存率均为零。然而,在1978年至1989年期间,HAL组的5年生存率为零,HAI组为7.9%,HAL+HAI组为24.4%(10例患者进行了二次探查切除),HAL+HAI+放疗组为36.5%(19例进行了二次探查切除)。后期生存率的显著提高归因于肝动脉导管置入位置准确、化疗灌注时间延长以及联合治疗,特别是部分患者进行了二次探查切除。这些结果表明,HAL+HAI+联合治疗可能会延长某些原本无法切除的PLC患者的生存期,甚至有可能实现切除。